In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Tissue tricuspid annular displacement - a new speckle tracking tool for functional assessment of the right ventricle

Session Poster session 6

Speaker Filip Pawliczak

Congress : EuroEcho-Imaging 2017

  • Topic : imaging
  • Sub-topic : Echocardiography: Systolic and Diastolic Function
  • Session type : Poster Session
  • FP Number : P1540

Authors : F Pawliczak (Lodz,PL), JD Kasprzak (Lodz,PL), P Lipiec (Lodz,PL)

Authors:
F Pawliczak1 , JD Kasprzak2 , P Lipiec1 , 1Medical University of Lodz, Rapid Cardiac Diagnostics Unit - Lodz - Poland , 2Medical University of Lodz, Department of Cardiology - Lodz - Poland ,

Citation:
European Heart Journal Supplements ( 2017 ) 18 ( Supplement 3 ), iii385

Background:
Tissue tricuspid annular displacement (TTAD) is a new echocardiographic tool for functional assessment of right ventricle (RV) based on speckle tracking. It allows measurement of the displacement of the tricuspid annulus relative to the apex of RV in the standard apical four chamber (4CH) view.
The aim of this study is investigation if TTAD analysis might be used interchangeably with commonly used echocardiographic RV functional markers.

Methods:
In this retrospective study we included 65 patients (44 men, mean age 63,89±14,68 years), who underwent 2D transthoracic echocardiographic examination. Two patients were excluded due to insufficient visualization of RV. Tricuspid annular plane systolic excursion (TAPSE) was measured.  Afterward, off-line measurements of RV fractional area change (RV FAC), as well as line measurements of TTAD were obtained in 62 patients; 1 person was excluded due to artifacts affecting the proper analysis.

Results:
The feasibility of TTAD is 95,4%. Mean values of RV FAC, the midpoint tricuspid annulus displacement towards the RV apex (TTAD mpt) and the percentage of the midpoint tricuspid annulus displacement (TTAD%) were 40,2±12,9%, 10,3±4,6 mm and 15±6,7%, respectively. The distribution of TAPSE values was not normal, therefore Spearman’s rank correlation was performed for TAPSE vs TTAD mpt (rho=0,603, p<0,0001) & TAPSE vs TTAD% (rho=0,637, p<0,0001). Due to normal distribution of RV FAC, correlation coefficient was checked for RV FAC vs TTAD mpt (r=0,4448, p=0,0003) & RV FAC vs TTAD% (r=0,519, p<0,0001). TAPSE also correlated with RV FAC (rho=0,459, p=0,0002). AUC for TTAD mpt and TTAD% for detecting RV dysfunction defined as TAPSE <17 mm were 0,828 (p=0,0001) and 0,834 (p=0,0001) respectively. The threshold value of TTAD mpt of =11,5 mm had 100% sensitivity and 52,1% specificity, whereas the threshold for TTAD% of =11,9% had 78,6% sensitivity and 72,9% specificity.

Conclusions:
TTAD analysis results correlate significantly with well-established RV function parameters such as TAPSE & RV FAC and it is applicable in a similar number of patients.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are